<< Вернуться к списку статей журнала

Том 6 №2 2004 год - Нефрология и диализ

Роль оксидативного стресса в патологии сердечно-сосудистой системы у больных с заболеваниями почек (Сообщение II. Клинические аспекты оксидативного стресса)

Саенко Ю.В. Шутов А.М.

Аннотация: Причиной возникновения оксидативного стресса является увеличение продукции свободных радикалов и (или) снижение эффективности антиоксидантных систем организма. Сообщение II касается клинических аспектов оксидативного стресса у больных с патологией почек. Представлены данные о связи оксидативного стресса с эндотелиальной дисфункцией, анемией, атеросклерозом. Обобщены данные литературы об оксидативном стрессе у больных с ХПН, получающих заместительную терапию. Приведены данные о влиянии ингибиторов АПФ, статинов, витамина Е на перекисное окисление липидов у больных заболеваниями почек. * Часть I данного сообщения опубликована в журнале «Нефрология и диализ» 2004; т. 6; № 1

Для цитирования: Саенко Ю.В., Шутов А.М. Роль оксидативного стресса в патологии сердечно-сосудистой системы у больных с заболеваниями почек (Сообщение II. Клинические аспекты оксидативного стресса). Нефрология и диализ. 2004. 6(2):138-144. doi:

Весь текст

Ключевые слова: заболевания почек, оксидативный стресс, сердечно-сосудистая патология, хроническая почечная недостаточность

Список литературы:

1. Ермоленко В.М., Яровая Г.А., Шутов Е.В., Грабская Е.С. Дислипидемии у больных с терминальной уремией на постоянном амбулаторном перитонеальном диализе (ПАПД). Нефрология и диализ 2002; 2: 118-120.
2. Перова Н.В. Атерогенные нарушения метаболизма липидов. Нефрология и диализ 2001; 3: 325-327.
3. Смирнов А.В. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 2: 8-14.
4. Ahotupa M., Vasankari T.J. Baseline diene conjugation in LDL lipids: An indicator of circulating oxidized LDL. Free Radic Biol Med 1999; 27: 1141-1150.
5. Allegra V., Mengozzi G., Martimbianco L., Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 1996; 16: 304-308.
6. Amann K., Tornig J., Buzello M. et al. Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int 2002; 62: 877-884.
7. Annuk M., Zilmer M., Lind L. et al. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-2752.
8. Arnal J.F., Dinh-Xuan A.T., Pueyo M. et al. Endotelial-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55: 1078-1097.
9. Balascas E.V., Melamed I.R., Gupta A. et al. Effect of erythropoietin treatment on nutritional status of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13: S544-S549.
10. Bartfay W.J., Butany J., Lehotay D.C. et al. A biochemical, hystochemical and electron microscopic study on the effects of iron-loading on the hearts of mice. Cardiovasc Pathol 1999; 8: 305-314.
11. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707-727.
12. Beusterien K.M., Nissenson A.R., Port F.K. et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773.
13. Boaz M., Smetana S., Weinstein T. et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomized placebo-controlled trial. LANCET 2000; 356: 1213-1218.
14. Bommer J., Kugel M., Schwobel B. et al. Improved sexual function during recombinant erythropoietin therapy. Nephrol Dial Transplant 1990; 5: 204-207.
15. Borawski J., Pawlak K., Naumnik B., Mysliwiec M. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients. Ren Fail 2002; 24: 825-837.
16. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87: 840-844.
17. Canesrtani F., Buoncristiani U., Galli F. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 1995; 234: 127-136.
18. Canestrari F., Galli F., Giorgini A. et al. Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994; 91: 187-193.
19. Carluccio F., Siems W., Stefanelli G. et al. Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Clin Nephrol 2002l; 58 (Suppl. 1): S26-S30.
20. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M. et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-853.
21. Channon K.M., Qian H., George S.E. Nitric oxide synthase in atherosclerosis and vascular injury: insights from experimental gene therapy. Arterioscler Thromb Vasc Biol 2000; 20: 1873-1881.
22. Clipstein-Grobusch K., Kostner J.F. et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999; 69: 1231-1236.
23. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037.
24. Costagiola C., Romano L., Sorice P., Di Benedetto A. Anemia and chronic renal failure: The possible role of the oxidative state of glutatione. Nephron 1989; 52: 11-14.
25. Covdar C., Camsari T., Semin I. et al. Lipid peroxidation and antioxidant activity in chronic hemodialysis patients with recombinant human erythropoietin. Scand J Urol Nephrol 1997; 31: 371-375.
26. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
27. Dascher M., Lanhartz H., Botticher D. et al. Influence of dialysis on plasma lipid peroxidation products and antioxidants levels. Kidney Int 1996; 50: 1268-1272.
28. Dasgupta A., Hussain S., Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992; 55: 56-59.
29. Dechend R., Mьller D., Park J.K. et al. Statins and angiotensin II-induced vascular injury. Nephrol Dial Transplant 2002; 17: 349-353.
30. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-416.
31. Dimmeler S., Fleming I., Fisslthaler B. et al. Activation of nitric oxide synthase in endothelial cells by AKT-dependent phosphorylation. Nature 1999; 399: 601-605.
32. Donate T., Herreros A., Martinez E. et al. Protein oxidative stress in dialysis patients. Adv Perit Dial 2002; 18: 15-17.
33. Drueke T., Witko-Sarsat V., Massy Z. et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217.
34. Duffy S.J., Biegelsen E.S., Holbrook M. et al. Iron helation improves endothelial function in patients with coronary artery disease. Circulation 2001; 103: 2799-2804.
35. Eckardt K.-U. Pathophysiology of renal anemia. Clin Nephrol 2000; 53 (Suppl. 1): S2-S8.
36. Epperlein M.M., Nourooz-Zadeh J., Jayasena S.D. et al. Nature and biological significance of free radicals generated during bicarbonate hemodialysis. J Am Soc Nephrol 1998; 9: 457-463.
37. Erslev A.J., Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia in chronic renal failure. Kidney Int 1997; 51: 622-630.
38. Feldman H.I., Santanna J., Guo W. et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744.
39. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-2137.
40. Griendling K.K., Mimeri C.A., Ollerenshaw J.D. et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
41. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
42. Grune T. et al. Oxidative stress in anemia. Clin Nephrol 2000; 53 (Suppl. 1): 18-22.
43. Haag-Weber M., Horl W.H. Dysfunction of polymorphonuclear leucocytes in uremia. Semin Nephrol 1996; 16: 192-201.
44. Haklar G., Yegenaga I., Yalcin A.S. Evaluation of oxidant stress in chronic hemodialysis patients: use of different parameters. Clin Chim Acta 1995; 234: 109-114.
45. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23 (Suppl. 1): 118-126.
46. Harrison D.G. Cellular and molecular mechanisms of endothelial dysfunction? J Clin Invest 1997; 100: 2153-2157.
47. Hasdan G., Benchetrit S., Rashid G. et al. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002; 61: 586-590.
48. Henning B., Chow C.K. Lipid peroxidation and endothelial cell injury: Implications in atherosclerosis. Free Radic Biol Med 1988; 4: 9-100.
49. Himmelfarb J., McMenamin M.E., Loseto G., Heinecke J.W. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-1169.
50. Hoenich N.A. Platelet and leucocytes behaviour during haemodialysis. Contrib Nephrol 1999; 125: 120-132.
51. Holvoet P., Cleemput J., Collen D., Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 29: 698-702.
52. Hцrl W.H. Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13: S62-S71.
53. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme in humans. Circulation 1997; 95: 1115-1118.
54. Jackson P., Loughrey C.M., Lightbody J.H. et al. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. 1995; 41: 1135-1138.
55. Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
56. Joannides R., Bakkali E.H., Le Roy F. et al. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2623-2628.
57. Johnstone M.T., Creager S.J., Scales K.M. et al. Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-2516.
58. Kalantar-Zadeh K., Rodrigues R., Humphreys M.H. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37: 564-572.
59. Kiechl S., Willeit J., Egger G. et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300-3307.
60. Kletzmayr J., Hцrl W.H. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002; 17 (Suppl. 2): 27-32.
61. Koken T., Serteser M., Kahraman A., Gokce C. Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 2002; 15: 302-307.
62. Krane V., Wanner C. The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease. Nephrol Dial Transplant 2002: 17 (Suppl. 11): 23-27.
63. Kurowska E.M. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8: 155-166.
64. Kuryshev Y.A., Brittenham G.M., Fujioka H. et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocites. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 1999; 100: 675-683.
65. Laufs U., La F.V., Plutzky J. et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
66. Lindholm L.H., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359; 1004-1010.
67. Link G., Konijn A.M., Hershko C. Cardioprotective effects of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med 1999; 133: 179-188.
68. Lonn E., Yusuf S., Dzavuc V. et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.
69. Loughrey C.M., Young I.S., Lightbody J.H. et al. Oxidative stress in hemodialysis. Q J Med 1994; 87: 679-683.
70. Lucchi L., Bergamini S., Botti B. et al. Influence of different hemodialysis membranes on red blood cell susceptibility to oxidative stress. Artif Organs 2000; 24: 1-6.
71. Ludat K., Sommerburg O., Grune T. et al. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000; 53 (Suppl. 1): S30-S35.
72. Macdougall I.C., Lewis N.P., Saunders M.J. et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493.
73. Mancini G.B., Henry G.C., Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258-265.
74. Marrades P.M., Roca J., Campistol J.M. et al. Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure. J Clin Invest 1996; 97: 2092-2100.
75. Massy Z.A., Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol 2002; 15: 336-341.
76. Mimic-Oka J., Simic T., Djukanovic L. et al. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999; 51: 233-241.
77. Mimic-Oka J., Simic T., Djukanovic L.J. et al. Glutatione and its associated enzymes in peripheral blood cells in different stages of renal insufficiency. Amino Acids 1992; 2: 215-224.
78. Miyata T., Horie K., Ueda Y. et al. Advanced glycation and lipoperoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435.
79. Miyazaki H., Matsuoka H., Itabe H. et al. Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-1006.
80. Moncada S., Hill J.A. The L-arginin-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
81. Mune M., Yukawa S., Kishino M. et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 1999; 56 (Suppl. 71): S126-S129.
82. Mydlik M., Derzsiova K., Racz O. et al. Vitamin E as an antioxidant agent in CAPD patients. Int J Artif Organs 2002; 25: 373-378.
83. Nenov D., Paskalev D., Yankova T., Tchankova T. Lipid peroxidation and vitamin E in red blood cells and plasma in hemodialysis patients under rhEPO treatment. Artif Organs 1995; 19: 436-439.
84. Nickening G., Harrison D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
85. O’Driscoll G., Green D., Taylor R.R. et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation 1997; 95: 1126-1131.
86. Ortego M., Bustos C., Hernandez-Presa M.A.J. et al. Atorvastatin reduces NF-kB activation and chemokine expression in vascular smooth muscle cells. Atherosclerosis 1999; 147: 253-261.
87. Oskarsson H.J., Heistad D.D. Oxidative stress produced by angiotensin too. Implications for hypertension and vascular injury. Circulation 1997; 95: 557-559.
88. Ozden M., Maral H., Akaydin D. et al. Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002; 35: 269-273.
89. Panza J.A., Quyyumi A.A., Brush J.E., Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
90. Pfeilschifter J. Nitric oxide triggers the expression of proinflammatory and protective gene products in mesangial cells and the inflamed glomerulus. Nephrol Dial Transplant 2002; 17: 347-348.
91. Radermacher J., Koch K.M. Treatment of renal anemia by erythropoietin substitution - The effect on the cardiovascular system. Clin Nephrol 1995; 44: S56-S60.
92. Roob J.M., Khoschsorur G., Tiran T. et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549.
93. Ross E.A., Koo L.C., Moberly J.B. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1997; 30: 489-494.
94. Salonen J.T., Korpela H., Nyyssonen K. et al. Association body iron stores and the risk of acute myocardial infarction in men. Circulation 1998; 97: 1461-1466.
95. Schдchinger V., Zeiher A.M. Atherogenesis - recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplan 2002; 17: 2055-2064.
96. Schultz D., Harrison D.G. Quest for fire: seeking the source of pathogenic oxygen radicals in atherosclerosis (Editorial). Arterioscler Thromb Vasc Biol 2000; 20: 1412-1413.
97. Sennesael J.J., Van der Niepen P., Verbeelen D. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121-128.
98. Shurtz-Swirski R., Kristal B., Shasha S.M. et al. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in continuous ambulatory dialysis patients. Nephron 2002; 91: 759-761.
99. Siems W., Carluccio F., Grune T. Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin Nephrol 2002; 58 (Suppl. 1): S20-S25.
100. Siems W., Quast S., Carluccio F. et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 2002; 58 (Suppl. 1): S12-S19.
101. Siems W.G., Kramer K., Grune T., Esterbauer H. Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-Dihydroxynonenal is not the main product. J Lipid Res 1997; 38: 612-622.
102. Siems W.G., Pimenov A.M., Esterbauer H., Grune T. Metabolism of 4-hydroxynonenal, a cytotoxic lipid peroxidation product in thymocytes as an effective secondary antioxidative defense mechanism. Biochemistry Tokyo 1998; 123: 534-539.
103. Sommerburg O., Grune T., Hampl H. et el. Does long-term treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialyzed patients? Nephrol Dial Transplant 1988; 13: 2583-2587.
104. Sullivan J.L. Iron therapy and cardiovascular disease. Kidney Int 1999; 55 (Suppl. 69): S135-S137.
105. Sullivan J.L., Zacharski L.R. Hereditary haemochromatosis and the hypotesis that iron depletion protects against ischemic heart disease. Eur J Clin Invest 2001; 31: 375-377.
106. Tercedor J., Lopez-Hernandes B., Rodenas J.M. et al. Erythropoietin therapy for uremic pruritis. N Engl J Med 1991; 327: 734.
107. Tsunekawa T., Hayashi T., Kano H. et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379.
108. Tsuruoka S., Kawaguchi A., Nishiki K. et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis 2002; 39: 127-133.
109. United States Renal Data System. USRDS Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 1999.
110. Vaziri N.D., Dicus M., Ho N.D. et al. Oxidative stress and dysregulation of superoxide dismutase and NADPH dismutase in renal insufficiency. Kidney Int 2003; 63: 179-185.
111. Vaziri N.D., Ni Z., Oveisi F. et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-141.
112. Vigano G., Benigni A., Mendogni D. et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 18: 44-49.
113. Wanner C. Importance of hyperlipidemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 (Suppl. 5): 92-96.
114. Westhuyzen J., Adams C.E., Elemming S.J. Evidence for oxidative stress during in vitro dialysis. Nephron 1995; 70: 49-54.
115. Wever R.M., Luscher T.F., Cosentino F. et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
116. Wolin M.S. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000; 20: 1430-1442.
117. Wood D., De Backer G., Faergeman O. et al. and members of the second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-1503.
118. Yogo K., Shimokawa H., Funakoshi H. et al. Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol 2000; 20: E96-E100.
119. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
120. Zachara B.A., Trafikowska U., Adamowicz A. et al. Selenium, glutathione peroxidases, and some other antioxidant parameters in blood of patients with chronic renal failure. J Trace Elem Med Biol 2001; 15: 161-166.
121. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002; 17 (Suppl. 11): 50-54.

Другие статьи по теме

• Роль оксидативного стресса в патологии сердечно-сосудистой системы у больных с заболеваниями почек (Сообщение I. Патофизиология оксидативного стресса)
• Диастолическая дисфункция у больных с хронической почечной недостаточностью
• Артериальная гипертензия и почки (По материалам 9-й Европейской конференции по кардионефрологии, Ассиси, Италия, 11-13 апреля 2002 года)
• Современные подходы к иммунопрофилактике инфекций у пациентов с заболеваниями почек (Обзор литературы)